Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Chris Parker,Noel W. Clarke,Adrian Cook,Howard Kynaston,Peter Meidahl Petersen,Charles Catton,William Cross,John P Logue,Wendy R. Parulekar,Heather Payne,Rajendra Persad,Holly Pickering,Fred Saad,Juliette Anderson,Amit Bahl,David Bottomley,Klaus Brasso,Rohit Chahal,Peter Cooke,Ben Eddy,Stephanie Gibbs,Chee Goh,Sandeep Gujral,Catherine Heath,Alastair Henderson,Ramasamy Jaganathan,Henrik Jakobsen,Nicholas D. James,S.K. Sundaram,Kathryn Lees,Jason F. Lester,Henriette Lindberg,Julian Money-Kyrle,S L Morris,Joe M. O'Sullivan,Peter Ostler,Lisa Owen,Prashant Patel,Alvan Pope,Alvan Pope,Alvan Pope,Rick Popert,Rakesh Raman,Martin Andreas Røder,Ian Sayers,Matthew S. Simms,James M. Wilson,Anjali Zarkar,Mahesh K. B. Parmar,Matthew R. Sydes +49 more
Reads0
Chats0
TLDR
The initial results do not support routine administration of adjuvant radiotherapy after radical prostatectomy, and an observation policy with salvage radiotherapy for PSA biochemical progression should be the current standard after radical Prostate cancer.About:
This article is published in The Lancet.The article was published on 2020-10-31 and is currently open access. It has received 200 citations till now. The article focuses on the topics: Salvage therapy & Radiation therapy.read more
Citations
More filters
Journal ArticleDOI
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Claire L Vale,David Fisher,Andrew Kneebone,Chris Parker,Maria Pearse,Pierre Richaud,Paul Sargos,Matthew R. Sydes,Christopher D. Brawley,Meryem Brihoum,Chris Brown,Sylvie Chabaud,Adrian Cook,Silvia Forcat,Carol Fraser-Browne,Igor Latorzeff,Mahesh K. B. Parmar,Jayne F. Tierney +17 more
TL;DR: A collaborative and prospectively designed systematic review and meta-analysis suggests that adjuvant radiotherapy does not improve event-free survival in men with localised or locally advanced prostate cancer.
Journal ArticleDOI
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Andrew Kneebone,Andrew Kneebone,Carol Fraser-Browne,Gillian M. Duchesne,Gillian M. Duchesne,Richard Fisher,Mark Frydenberg,Alan Herschtal,Scott Williams,Scott Williams,Chris Brown,Warick Delprado,Warick Delprado,Annette Haworth,David Joseph,Jarad Martin,Jarad Martin,John H L Matthews,Jeremy Millar,Mark Sidhom,Mark Sidhom,Nigel Spry,Nigel Spry,Colin Tang,Colin Tang,Sandra Turner,K. Wiltshire,Henry H. Woo,Henry H. Woo,Ian D. Davis,Tee S Lim,Maria Pearse +31 more
TL;DR: Data support the use of salvage radiotherapy as it results in similar biochemical control to adjuvant radiotherapy, spares around half of men from pelvic radiation, and is associated with significantly lower genitourinary toxicity.
Journal ArticleDOI
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Paul Sargos,Sylvie Chabaud,Igor Latorzeff,Nicolas Magné,A. Benyoucef,Stéphane Supiot,David Pasquier,Menouar Samir Abdiche,Olivier Gilliot,Pierre Graff-Cailleaud,Marlon Silva,Philippe Bergerot,Pierre Baumann,Yazid Belkacemi,David Azria,Meryem Brihoum,Michel Soulié,Pierre Richaud +17 more
TL;DR: A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events, and a policy of adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction.
Journal ArticleDOI
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial
Ashesh B. Jani,Eduard Schreibmann,Subir Goyal,Raghuveer Halkar,Bruce Hershatter,Peter J. Rossi,Joseph W. Shelton,Pretesh Patel,Karen M. Xu,Mark M. Goodman,Viraj A. Master,Shreyas S. Joshi,Omer Kucuk,Bradley C. Carthon,Mehmet Asim Bilen,Olayinka A. Abiodun-Ojo,Akinyemi A. Akintayo,Vishal R. Dhere,David M. Schuster +18 more
TL;DR: The role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy was evaluated in the EMPIRE-1 trial as mentioned in this paper.
Journal ArticleDOI
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
TL;DR: The SPORT trial as mentioned in this paper was designed to determine whether incremental gains in patient outcomes can be achieved by adding either 4-6 months of short-term androgen deprivation therapy (ADT) to PBRT, or both shortterm ADT and pelvic lymph node radiotherapy (PLNRT) to pBRT.
References
More filters
Journal ArticleDOI
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
TL;DR: The Late Morbidity Scoring Criteria were developed as a joint effort between physicians with renewed interests in fast neutron therapy and Radiation Therapy Oncology Group (RTOG) staff to represent cumulative probabilities of late effects with methods similar to those for estimating local control and survival.
Journal ArticleDOI
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
Michel Bolla,Hendrik Van Poppel,Laurence Collette,Paul Van Cangh,K. Vekemans,Luigi F. Da Pozzo,Theo M. de Reijke,Antony Verbaeys,Jean-François Bosset,Roland Van Velthoven,Jean-Marie Maréchal,Pierre Scalliet,Karin Haustermans,Marianne Pierart +13 more
TL;DR: Immediate external irradiation after radical prostatectomy improves biochemical progression-free survival and local control in patients with positive surgical margins or pT3 prostate cancer who are at high risk of progression.
Journal ArticleDOI
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Michel Bolla,Hein Van Poppel,Bertrand Tombal,K. Vekemans,Luigi F. Da Pozzo,Theo M. de Reijke,Antony Verbaeys,Jean-François Bosset,Roland Van Velthoven,Marc Colombel,Cees van de Beek,Paul C.M.S. Verhagen,Alphonsus C.M. van den Bergh,Cora N. Sternberg,Thomas C. Gasser,Geertjan van Tienhoven,Pierre Scalliet,Karin Haustermans,Laurence Collette +18 more
TL;DR: Results at median follow-up of 10·6 years show that conventional postoperative irradiation significantly improves biochemical progression-free survival and local control compared with a wait-and-see policy, supporting results at 5 year follow- up; however, improvements in clinical progression- free survival were not maintained.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicolas James,Philip W. Kantoff,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,Chris Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin +60 more
TL;DR: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.
Journal ArticleDOI
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
William U. Shipley,W. Seiferheld,H. Lukka,Pierre Major,Niall M. Heney,David J. Grignon,Oliver Sartor,Maltibehn P. Patel,Jean Paul Bahary,Anthony L. Zietman,Thomas M. Pisansky,Kenneth L. Zeitzer,Colleen A. Lawton,Felix Y. Feng,Richard Dana Lovett,Alexander Balogh,Luis Souhami,Seth A. Rosenthal,Kevin J. Kerlin,James J. Dignam,Stephanie L. Pugh,Howard M. Sandler +21 more
TL;DR: The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long‐term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo.
Related Papers (5)
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Michel Bolla,Hein Van Poppel,Bertrand Tombal,K. Vekemans,Luigi F. Da Pozzo,Theo M. de Reijke,Antony Verbaeys,Jean-François Bosset,Roland Van Velthoven,Marc Colombel,Cees van de Beek,Paul C.M.S. Verhagen,Alphonsus C.M. van den Bergh,Cora N. Sternberg,Thomas C. Gasser,Geertjan van Tienhoven,Pierre Scalliet,Karin Haustermans,Laurence Collette +18 more
Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial
Thomas Wiegel,Detlef Bartkowiak,Dirk Bottke,Claudia Bronner,Ursula Steiner,Alessandra Siegmann,Reinhard Golz,Stephan Störkel,Normann Willich,Axel Semjonow,Michael Stöckle,Christian Rübe,Udo Rebmann,T. Kälble,Horst Jürgen Feldmann,Manfred P. Wirth,Rainer Hofmann,Rita Engenhart-Cabillic,Axel Hinke,Wolfgang Hinkelbein,Kurt Miller +20 more
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
William U. Shipley,W. Seiferheld,H. Lukka,Pierre Major,Niall M. Heney,David J. Grignon,Oliver Sartor,Maltibehn P. Patel,Jean Paul Bahary,Anthony L. Zietman,Thomas M. Pisansky,Kenneth L. Zeitzer,Colleen A. Lawton,Felix Y. Feng,Richard Dana Lovett,Alexander Balogh,Luis Souhami,Seth A. Rosenthal,Kevin J. Kerlin,James J. Dignam,Stephanie L. Pugh,Howard M. Sandler +21 more